These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15723258)

  • 1. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
    O'Reilly T; Wartmann M; Maira SM; Hattenberger M; Vaxelaire J; Muller M; Ferretti S; Buchdunger E; Altmann KH; McSheehy PMJ
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):307-317. PubMed ID: 15723258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carvedilol in glioma treatment alone and with imatinib in vitro.
    Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
    Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
    Pietras K; Stumm M; Hubert M; Buchdunger E; Rubin K; Heldin CH; McSheehy P; Wartmann M; Ostman A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3779-87. PubMed ID: 14506171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
    O'Reilly T; McSheehy PM; Wenger F; Hattenberger M; Muller M; Vaxelaire J; Altmann KH; Wartmann M
    Prostate; 2005 Nov; 65(3):231-40. PubMed ID: 15948135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    Corcoran NM; Costello AJ
    BJU Int; 2005 Sep; 96(4):640-6. PubMed ID: 16104925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
    Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
    Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
    Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
    Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
    Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
    Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
    Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM
    Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
    Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
    Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
    Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
    Becquet M; Laborde L; Texier C; Sterker D; Gschwind HP; Pfaar U; Wartmann M; O'Reilly TM; McSheehy PM
    Anticancer Drugs; 2018 Aug; 29(7):691-701. PubMed ID: 29734209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
    Oehler C; von Bueren AO; Furmanova P; Broggini-Tenzer A; Orlowski K; Rutkowski S; Frei K; Grotzer MA; Pruschy M
    Neuro Oncol; 2011 Sep; 13(9):1000-10. PubMed ID: 21743064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
    Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.